与抗体药物联结物相关的间歇性肺病:FAERS数据库的数据挖掘
Zicheng Yu1, Haibin Zhu1, Xiaolan Liao1
1Department of Pharmacy, Yangpu Hospital, School of Medicine, Tongji University, Shanghai, China.
Expert opinion on drug safety
|September 4, 2024
概括
间歇性肺部疾病 (ILD) 是一种与抗体-药物联合体 (ADC) 相关的严重不良事件. 这项研究发现了11个ADC的强烈ILD信号,其中Trastuzumab deruxtecan显示出最显著的关联.
科学领域:
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
- 肺部病理学 肺部病理学
背景情况:
- 抗体-药物合物 (ADC) 与严重的不良事件有关,包括间歇性肺部疾病 (ILD).
- 了解不同ADC的ILD的特定风险对于患者的安全至关重要.
研究的目的:
- 调查和量化ADCs和间歇性肺病 (ILD) 的不良事件之间的关联.
- 为了确定具有最强的ILD信号的特定ADC.
主要方法:
- 从FDA不良事件报告系统 (FAERS) 数据库 (2004年第一季度 - 2023年第四季度) 中分析了1389份不良事件报告.
- 使用报告几率比率 (ROR) 和多项性马鱼缩小器 (MGPS) 方法进行信号挖掘.
- 使用Python,R和MySQL进行数据管理和分析.
主要成果:
- 在所有11个研究的ADC中检测到强烈的ILD不良事件信号.
- 根据ROR和MGPS分析,Trastuzumab deruxtecan表现出最强的ILD信号.
- 对于ILD的中位数发病时间在ADC中变化在8到207天之间.
结论:
- 抗胰岛素和ILD不良事件之间的关联是显著的,需要密切监测.
- 临床使用ADC需要仔细评估ILD风险与治疗益处.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...


